全文获取类型
收费全文 | 461篇 |
免费 | 21篇 |
出版年
2023年 | 3篇 |
2021年 | 13篇 |
2020年 | 5篇 |
2019年 | 7篇 |
2018年 | 6篇 |
2017年 | 7篇 |
2016年 | 11篇 |
2015年 | 17篇 |
2014年 | 17篇 |
2013年 | 31篇 |
2012年 | 15篇 |
2011年 | 18篇 |
2010年 | 10篇 |
2009年 | 19篇 |
2008年 | 26篇 |
2007年 | 28篇 |
2006年 | 14篇 |
2005年 | 14篇 |
2004年 | 15篇 |
2003年 | 8篇 |
2002年 | 9篇 |
2001年 | 10篇 |
2000年 | 3篇 |
1999年 | 8篇 |
1998年 | 8篇 |
1997年 | 5篇 |
1996年 | 4篇 |
1995年 | 3篇 |
1994年 | 5篇 |
1993年 | 4篇 |
1992年 | 9篇 |
1991年 | 7篇 |
1990年 | 8篇 |
1989年 | 4篇 |
1988年 | 12篇 |
1987年 | 8篇 |
1986年 | 6篇 |
1985年 | 5篇 |
1984年 | 7篇 |
1983年 | 5篇 |
1982年 | 5篇 |
1981年 | 3篇 |
1980年 | 4篇 |
1979年 | 9篇 |
1978年 | 8篇 |
1977年 | 6篇 |
1976年 | 5篇 |
1974年 | 11篇 |
1973年 | 4篇 |
1972年 | 4篇 |
排序方式: 共有482条查询结果,搜索用时 31 毫秒
1.
Condon Tom Hakim Abbas Moran Antonio B. Zenteno Blumstein Daniel T. 《Journal of Ethology》2021,39(1):89-96
Journal of Ethology - Animals emit predator-elicited calls in response to potential predation threats. These vocalizations induce a variety of anti-predator behaviors in conspecific receivers... 相似文献
2.
3.
A. A. Hakim 《Cancer immunology, immunotherapy : CII》1980,8(2-3):133-141
Summary A lipid-like factor (LLF) of a phospholipid nature was isolated from spent cell-free media of explants and cell cultures from lipids collected from human mammary carcinoma and malignant melanoma cells. LLF modulates macrophage properties and inhibits macrophage chemotactic activity, spreading, lipopolysaccharide-induced tumoricidal activities, and macrophage migration. LLF is unique to tumor cells and is not present in detectable quantities in normal mammary epithelial cells or skin fibroblasts. LLF also inhibits human normal lymphocytes' response to mitogenic stimulation. Partial purification of LLF from human mammary carcinoma is attained by a combination of chloroform extraction and filtration through Amicon molecular membranes. LLF activity is not sensitive to trypsin, pronase, bovine spleen phosphodiesterase II, alkaline phosphatase, or ribonuclease, but it is completely inactivated with phospholipase and lipoprotein lipase. 相似文献
4.
5.
6.
7.
Jeni P. Mahida Christophe Antczak Daniel DeCarlo Kathryn G. Champ Jasmine H. Francis Brian Marr Arthur S. Polans Daniel M. Albert David H. Abramson Hakim Djaballah 《PloS one》2013,8(3)
For many cancers, the lack of potency and the toxicity of current drugs limits the dose achievable in patients and the efficacy of treatment. Among them, retinoblastoma is a rare cancer of the eye for which better chemotherapeutic options are needed. Combination therapy is a compelling approach to enhance the efficacy of current treatment, however clinical trials to test rationally designed combinations of approved drugs are slow and expensive, and limited by our lack of in-depth knowledge of drug specificity. Since many patients already turn to nutraceuticals in hopes of improving their condition, we hypothesized that certain approved drugs could potentially synergize with widely consumed supplements. Following this hypothesis, we devised an alternative screening strategy aimed at taking advantage of a bait compound such as a nutraceutical with potential therapeutic benefits but low potency, by screening chemical libraries for approved drugs that synergize with this companion effector. As a proof of concept, we sought to identify approved drugs with synergetic therapeutic effects toward retinoblastoma cells in combination with the antioxidant resveratrol, popular as a supplement. We systematically tested FDA-approved drugs and known bioactives seeking to identify such pairs, which led to uncovering only a few additive combinations; but to our surprise, we identified a class of anticancer drugs widely used in the clinic whose therapeutic effect is antagonized with resveratrol. Our observations could explain in part why some patients do not respond well to treatment. Our results validate this alternative approach, and we expect that our companion effector strategy could significantly impact both drug discovery and the nutraceutical industry. 相似文献
8.
Attenuation of pulmonary and systemic vasoconstriction with pentoxifylline and aminophylline 总被引:1,自引:0,他引:1
The effects of acute administration of therapeutic doses (1-10 mg/kg) of pentoxifylline and aminophylline on the resistance of the systemic and pulmonary circuits in anaesthetized dogs and pigs were tested. During room air breathing, neither of the two substances caused a significant change in systemic vascular resistance (SVR) or pulmonary vascular resistance (PVR). During hypoxia (10% O2 and nitrogen), however, both substances caused a significant reduction in PVR (p less than 0.05) without affecting SVR. The largest dose of pentoxifylline decreased PVR from 7.8 +/- 2.8 to 4.4 +/- 1.5 in dogs and from 9.9 +/- 1.4 to 5.8 +/- 0.6 mmHg.L-1.min in pigs. Aminophylline was equally effective and selective in lowering PVR but not SVR during hypoxia. When SVR was elevated in dogs by continuous infusion of angiotensin, pentoxifylline lowered SVR from 139 +/- 27 to 83 +/- 20 mmHg.L-1.min (p less than 0.05). The simultaneous small elevation in PVR during angiotensin infusion was also attenuated to base-line value by pentoxifylline injection. These results suggest that xanthines, in therapeutic doses, can have a profound vasodilator effect on either the systemic or on the pulmonary circuit, only wherever the vessels are constricted. The vasodilatory effect of pentoxifylline is viewed as a second beneficial effect besides the benefit derived from its action on erythrocyte deformability. 相似文献
9.
Eman Saad Elzanfaly Enas Abdel Hakim Amer Sara Abdel Basset Galal Hala Elsayed Zaazaa 《Luminescence》2019,34(1):64-69
A spectrofluorimetric method for the determination of eptifibatide is presented based on its native fluorescence. The type of solvent and the wavelength of maximum excitation and emission were carefully selected to optimize the experimental conditions. Under the specified experimental conditions, the linearities obtained between the emission intensity and the corresponding concentrations of eptifibatide were in the range 0.1–2.5 μg/ml for the calibration curve constructed for direct determination of eptifibatide in dosage form and 0.05–2.2 μg/ml for the calibration curve constructed in spiked human plasma with a good correlation coefficient (r > 0.99). The lower limit of quantification for the calibration curve constructed in human plasma was 0.05 μg/ml. Recovery results for eptifibatide in spiked plasma samples and in dosage form, represented as mean ± % RSD, were 95.17 ± 1.94 and 100.29 ± 1.33 respectively. The suggested procedures were validated according to the International Conference on Harmonization (ICH) guidelines for the direct determination of eptifibatide in its pure form and dosage form and United States Food and Drug Administration (US FDA) Guidance for Industry, Bioanalytical Method Validation for the assay of eptifibatide in human plasma. 相似文献